Although K-RAS mutations are well known, there is a lack of effective therapeutic options available for K-RAS driven NSCLC.25 Severe side effects, multidrug resistance and poor survival outcomes are the limitations of current NSCLC therapies 28,29, indicating the urgency of developing an effective therapeutic for its treatment. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.